Skip to main content
MIST
NASDAQ Life Sciences

Milestone Q3: CFO and CMO Out, 30% Cost Cut, RTW PIK Extended to 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.7
Mkt Cap
$81.571M
52W Low
$0.631
52W High
$3.06
52W Position info
11% above low
Off High info
77% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MIST is trading near its 52-week low of $0.631 (11% above the low).

Summary

Milestone's Q3 8-K discloses the departure of its CFO and CMO, a ~30% operating expense cut, and an RTW amendment extending PIK interest to March 2029 — extending cash runway into late 2028, past the 2H 2028 AFib-RVR Phase 3 readout.


Key Events · Earnings and Guidance · MIST

  • CFO and CMO Depart

    CFO Amit Hasija and CMO David Bharucha have left the leadership team; Anthony Krick, VP of Finance, becomes Principal Financial and Principal Accounting Officer.

  • RTW PIK Period Extended to 2029

    An amendment to the Note Purchase Agreement with RTW Investments extends the payment-in-kind interest period on the $60.2 million senior secured convertible notes from March 31, 2027 to March 2029.

  • 30% Cost Cut, $2M One-Time Charges

    Operating expenses are to fall by approximately 30%, with about $2 million of one-time severance and conversion charges, completed by Q1 2027; the ~45-rep sales force moves in-house.

  • Cash Runway Into Late 2028

    $145.4 million of cash, equivalents and short-term investments at September 30, 2026 is expected to fund operations into late 2028, more than one year beyond prior guidance and past the 2H 2028 ReVeRA-301 readout.


Analysis · MIST · Life Sciences

The quarter itself was already public this morning via the 10-Q and press release, but this 8-K carries the pieces that change the story: both the CFO and CMO are gone, and RTW agreed to push payment-in-kind interest on the $60.2 million convertible notes from March 2027 to March 2029. That debt relief, combined with a roughly 30% operating expense cut, is what lets management claim cash lasts into late 2028 — past the ReVeRA-301 readout expected in the second half of 2028. The trade-off is a thinner leadership bench and a company that now depends on one commercial product and one Phase 3 program, with a Nasdaq sub-$1.00 notice already outstanding from October 23, 2026.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MIST was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.6M. The 52-week trading range was $0.63 to $3.06. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MIST - Latest Insights

MIST
Nov 13, 2026, 7:08 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7201
Real-time Price: $0.680 info
Change: -$0.0401 (-6%) info
Market Cap: $81.571M info
MIST
Nov 13, 2026, 6:49 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.6988
Real-time Price: $0.680 info
Change: -$0.0188 (-3%) info
Market Cap: $81.571M info
MIST
Oct 28, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.755349
Real-time Price: $0.680 info
Change: -$0.075349 (-10%) info
Market Cap: $81.571M info
MIST
Sep 03, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $0.680 info
Change: -$0.530 (-44%) info
Market Cap: $81.571M info
MIST
Sep 03, 2026, 10:47 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.680 info
Change: -$0.5491 (-45%) info
Market Cap: $81.571M info